Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06676085
- Locations
- 🇨🇳
Bing Sun, Beijing, Beijing, China
Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Fernando Sanchez
- Target Recruit Count
- 20
- Registration Number
- NCT06646328
- Locations
- 🇪🇸
Fernando Sánchez, Castellón De La Plana, Castellon, Spain
Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 224
- Registration Number
- NCT06583889
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Regional Hospital of Scranton
- Target Recruit Count
- 450
- Registration Number
- NCT06549842
- Locations
- 🇺🇸
Regional Hospital of Scranton, Scranton, Pennsylvania, United States
Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Jesper Kjaergaard
- Target Recruit Count
- 210
- Registration Number
- NCT06453876
- Locations
- 🇩🇰
Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
🇩🇰Copenhagen University Hospital, Herlev Gentofte Hospital, Herlev, Denmark
🇩🇰Copenhagen University Hospital Gentofte, Gentofte, Capital Region, Denmark
Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 90
- Registration Number
- NCT06442267
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2000
- Registration Number
- NCT06381661
Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Shen Lei
- Target Recruit Count
- 156
- Registration Number
- NCT06375616
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 180
- Registration Number
- NCT06365398
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Xuanwu Hospital, Capital Medical University., Beijing, China
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Xiaotong Hou
- Target Recruit Count
- 154
- Registration Number
- NCT06275555
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.